2024
Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil
Reis J, Azevedo J, de Oliveira A, de Oliveira Menezes A, Pedrosa M, dos Santos M, Ribeiro L, de Freitas H, Gouveia E, Teles M, da Glória Carvalho M, Reis M, Nascimento-Carvalho C, Verani J. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil. Vaccine 2024, 42: 591-597. PMID: 38184393, PMCID: PMC10872423, DOI: 10.1016/j.vaccine.2023.12.055.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosInvasive pneumococcal diseaseLower-middle-income settingsPCV10 introductionInvasive pneumococcal disease incidenceProspective laboratory-based surveillanceNational infant immunization programsPre-PCV10 periodNon-vaccine serotypesRate ratiosInfant immunization programIncidence ratePneumococcal conjugate vaccineLaboratory-based surveillanceIPD incidenceImpact of PCV10Multiplex polymerase chain reactionMetropolitan region of SalvadorCompare ratesPCV10 serotypesLong-term impactSterile sitesQuellung reactionSerotype 15BVaccine-type
2022
Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021
Perniciaro S, van der Linden M, Weinberger DM. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clinical Infectious Diseases 2022, 75: 1149-1153. PMID: 35136983, PMCID: PMC9383454, DOI: 10.1093/cid/ciac100.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD surveillance dataIPD casesIPD incidencePneumococcal diseaseNonpharmaceutical interventionsVaccine-serotype invasive pneumococcal diseaseSurveillance dataCoronavirus disease 2019 (COVID-19) pandemicSARS-CoV-2Disease 2019 pandemicVaccine serotypesChildren 0Baseline valuesAge groupsSerotype-specific variationPercentage changeOverall casesIncidenceNPI strategiesIPD levelAge distributionDiseaseBaselineSerotypes
2021
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Bennett JC, Hetrich MK, Quesada M, Sinkevitch JN, Knoll M, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, de Miguel S, De Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad’arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Khan A, Savrasova L, Scott JA, Skoczyńska A, Suga S, van der Linden M, Verani JR, von Gottberg A, Winje BA, Yildirim I, Zerouali K, Hayford K. Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms 2021, 9: 696. PMID: 33801760, PMCID: PMC8066231, DOI: 10.3390/microorganisms9040696.Peer-Reviewed Original ResearchInvasive pneumococcal diseasePneumococcal conjugate vaccinePneumococcal diseaseIncidence rateSerotype 1Streptococcus pneumoniae serotype 1Mixed-effects Poisson regressionInfant immunization programIntroduction of PCV10Pneumococcal serotype replacementIncidence rate ratiosIPD surveillance dataYears of ageIPD incidenceSerotype replacementLinear mixed-effects regressionConjugate vaccineBurden countriesImmunization programsMixed-effects regressionImportant causePoisson regressionSurveillance dataRate ratioPCV10/13
2020
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13
2018
1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Yildirim I, Little B, Shea K, Pelton S, Massachusetts M. 1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease. Open Forum Infectious Diseases 2018, 5: s441-s442. PMCID: PMC6253418, DOI: 10.1093/ofid/ofy210.1261.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseStreptococcus pneumoniaeIPD casesPneumococcal diseaseVaccine serotypesIncidence of IPDCommon clinical presentationIntroduction of PCV13Pneumococcal conjugate vaccineOverall mortality rateChildhood immunization scheduleSickle cell diseaseYears of ageEnhanced surveillance systemIPD incidenceCommon comorbiditiesConjugate vaccineMassachusetts childrenClinical presentationImmunization scheduleCurrent epidemiologyCNS diseaseHematologic malignanciesCell diseaseClinical data
2017
Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
Lapidot R, Shea K, Little B, Yildirim I, Pelton S. Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children. Open Forum Infectious Diseases 2017, 4: s467-s467. PMCID: PMC5631065, DOI: 10.1093/ofid/ofx163.1194.Peer-Reviewed Original ResearchPresence of comorbiditiesIPD casesPCV13 implementationYears of ageClinical syndromeSpeaker honorariaNP carriageNasopharyngeal carriageSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceAge distributionEffectiveness of PCV13Impact of PCV13US census estimatesInvasive pneumococcal diseasePneumococcal disease incidenceAnnual incidence rateActive Surveillance NetworkAnnual prevalence rateIPD incidenceMerck vaccinePCV13 dosePneumococcal diseaseVaccination statusVaccine serotypesInvasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13
Yildirim I, Little B, Pelton S. Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13. Open Forum Infectious Diseases 2017, 4: s67-s67. DOI: 10.1093/ofid/ofx162.159.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseYears of ageNonvaccine serotypesSpeaker honorariaStreptococcus pneumoniaePneumococcal diseaseVaccine serotypesIncidence of IPDImplementation of PCV13Common clinical presentationIntroduction of PCV13Overall mortality rateChildhood immunization scheduleChildren 6 yearsProportion of casesMA childrenEnhanced surveillance systemIPD incidenceMerck vaccineIPD casesConjugate vaccinePCV13 eraClinical presentationComorbid conditionsImmunization schedule
2013
Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease
Weinberger DM, Bruden DT, Grant LR, Lipsitch M, O'Brien KL, Pelton SI, Sanders EA, Feikin DR. Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease. American Journal Of Epidemiology 2013, 178: 1488-1495. PMID: 24013204, PMCID: PMC3813314, DOI: 10.1093/aje/kwt156.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD incidenceCarriage dataProportion of IPDPCV changesNasopharyngeal carriage studyNasopharyngeal pneumococcal carriagePre-PCV7 periodYears of agePCV7 introductionPneumococcal diseaseCarriage prevalenceNonvaccine serotypesPneumococcal carriageVaccine impactInvasive diseaseCarriage studiesHigh-quality surveillance systemsAmerican Indian populationsSerotype dataIncidenceIndian populationMixed effects modelsSerotypesVaccine
2011
Changing Disparities in Invasive Pneumococcal Disease by Socioeconomic Status and Race/Ethnicity in Connecticut, 1998–2008
Soto K, Petit S, Hadler JL. Changing Disparities in Invasive Pneumococcal Disease by Socioeconomic Status and Race/Ethnicity in Connecticut, 1998–2008. Public Health Reports 2011, 126: 81-88. PMID: 21836741, PMCID: PMC3150133, DOI: 10.1177/00333549111260s313.Peer-Reviewed Original ResearchConceptsRace/ethnicityNon-PCV7 serotypesSocioeconomic statusIncidence differenceCensus tract socioeconomic statusInvasive pneumococcal disease incidenceNeighborhood poverty levelInvasive pneumococcal diseasePneumococcal conjugate vaccinePneumococcal disease incidenceSterile body sitesRates of IPDHigh-poverty census tractsAbsence of vaccinesHigh rateIPD incidencePneumococcal diseaseConjugate vaccinePneumococcal isolatesTarget preventionLaboratory surveillancePoverty levelPercentage of peopleWhite peopleBody sites
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply